Therapeutic targets of congenital metabolic conditions have been experimentally observed in individuals living with cystic fibrosis (CF), in which polymorphisms of the Bsml gene were shown to affect VDR affinity for its primary substrates, leading to increased markers of oxidative stress and inflammation [92]. This evidence concerns the gene VDR and cystic fibrosis.